Cetera Investment Advisers increased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 0.9% in the 1st quarter, HoldingsChannel reports. The fund owned 29,848 shares of the biopharmaceutical company’s stock after buying an additional 253 shares during the quarter. Cetera Investment Advisers’ holdings in Bristol-Myers Squibb were worth $1,426,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Vanguard Group Inc increased its holdings in shares of Bristol-Myers Squibb by 1.0% in the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after acquiring an additional 1,229,553 shares in the last quarter. First Interstate Bank boosted its position in shares of Bristol-Myers Squibb by 0.9% during the fourth quarter. First Interstate Bank now owns 109,802 shares of the biopharmaceutical company’s stock worth $5,707,000 after buying an additional 1,010 shares during the period. Ardevora Asset Management LLP boosted its position in shares of Bristol-Myers Squibb by 13.6% during the fourth quarter. Ardevora Asset Management LLP now owns 518,088 shares of the biopharmaceutical company’s stock worth $26,930,000 after buying an additional 62,200 shares during the period. KBC Group NV boosted its position in shares of Bristol-Myers Squibb by 3.9% during the fourth quarter. KBC Group NV now owns 415,848 shares of the biopharmaceutical company’s stock worth $21,615,000 after buying an additional 15,465 shares during the period. Finally, Signet Investment Advisory Group Inc. acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $161,000. Institutional investors own 77.65% of the company’s stock.
Several research firms have recently weighed in on BMY. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research report on Tuesday, March 5th. BMO Capital Markets reaffirmed a “buy” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, February 19th. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. Bank of America reduced their price objective on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating for the company in a research report on Tuesday, February 19th. Finally, ValuEngine raised Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 4th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $56.69.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.01. The company had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a return on equity of 48.72% and a net margin of 22.23%. The firm’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.94 earnings per share. Equities research analysts predict that Bristol-Myers Squibb Co will post 4.18 earnings per share for the current year.
In other news, insider Karen Murphy Santiago sold 3,065 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $47.56, for a total transaction of $145,771.40. Following the transaction, the insider now owns 3,066 shares in the company, valued at $145,818.96. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Theodore R. Samuels II bought 5,000 shares of the stock in a transaction dated Thursday, May 16th. The shares were purchased at an average price of $47.29 per share, for a total transaction of $236,450.00. Following the purchase, the director now owns 27,000 shares of the company’s stock, valued at approximately $1,276,830. The disclosure for this purchase can be found here. 0.12% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4368951/cetera-investment-advisers-increases-position-in-bristol-myers-squibb-co-nysebmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: What are the benefits of a balanced fund?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.